Bristol Myers Squibb

The aim of this research study is to evaluate the safety and tolerability of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma. The names of the study drugs involved in this study are: * Iberdomide (a type of cereblon E3 ligase modulator) * Elotuzumab (a type of monoclonal antibody) * Dexamethasone (a type of steroid)Show more

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.Show more

The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity

This phase II trial tests the effectiveness of golcadomide and rituximab as bridging treatment before chimeric antigen receptor (CAR) T-cell therapy in patients with aggressive B-cell non-Hodgkin lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Patients that are able to receive CAR T-cell therapy have a potential for cure, however, many will not be qualified to receive therapy due to relapse. Bridging therapy is therapy intended to transition a patient from one therapy or medication to another or maintain their health or status until they are a candidate for a therapy or have decided on a therapy. Golcadomide may help block the formation, growth or spread of cancer cells. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving golcadomide and rituximab as bridging therapy before CAR T-cell therapy may kill more tumor cells and may improve the chance of proceeding to CAR T-cell therapy in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.Show more

The researchers are doing this study to find out whether combining teclistamab and mezigdomide is a safe and effective treatment approach in people with relapsed/refractory multiple myeloma (MM).

The purpose of the study is to determine the best treatment approach based on the risk profile of the cancer cells and on how the disease responds to treatment. This is a randomized research study evaluating treatment for transplant-eligible participants with newly diagnosed multiple myeloma (NDMM). Induction therapy in this study includes the drugs isatuximab, iberdomide, bortezomib, and dexamethasone. After induction therapy, participants will receive consolidation and maintenance therapy that is adapted based on their risk profile and response to treatment. The research study procedures include: screening for eligibility, study visits, blood and bone marrow tests, disease assessments, treatment with study drugs, and follow-up visits. It is expected that about 720 participants will take part in this study.Show more

Study of the combination of luspatercept in low-risk myelodysplastic syndrom (LR-MDS) without ring sideroblasts (RS) having failed or being ineligible to ESA

Bristol Myers Squibb is a global drug company based in Princeton, New Jersey, whose purchase of Celgene, completed in November 2019, made blood cancers and blood disorders a large part of its business. Most of its medicines treat common conditions such as cancer, heart disease and schizophrenia, but many of them are for rare diseases.

Its rare disease medicines include Revlimid, Pomalyst, Thalomid, Empliciti, Abecma and Zenbexus for multiple myeloma, Reblozyl for anemia in beta thalassemia and in very low to intermediate risk myelodysplastic syndromes, Onureg and Idhifa for acute myeloid leukemia, Inrebic for myelofibrosis, Breyanzi for mantle cell lymphoma and other lymphomas, Camzyos for obstructive hypertrophic cardiomyopathy, Augtyro for NTRK fusion cancers and Zeposia for multiple sclerosis.

In its pipeline, the FDA is reviewing mezigdomide for multiple myeloma that came back or stopped responding. Phase 3 programs include zola-cel, a CAR T-cell therapy, in systemic sclerosis, admilparant in idiopathic pulmonary fibrosis, Sotyktu in Sjögren's disease and RYZ101, a radiopharmaceutical, in neuroendocrine tumors of the gut and pancreas. It is also testing zola-cel in lupus, myositis, myasthenia gravis and immune cytopenias, and an experimental drug meant to raise fetal hemoglobin in sickle cell disease.

Bristol Myers Squibb has 16 FDA-approved drugs with a rare disease use that we track, as of November 2026.

Zeposia (ozanimod), approved 2020: Multiple Sclerosis.

Camzyos (mavacamten), approved 2022: Hypertrophic Cardiomyopathy.

Reblozyl (luspatercept), approved 2019: Beta-Thalassemia, Myelodysplastic Syndromes.

Augtyro (repotrectinib), approved 2024: NTRK Fusion Cancer.

Abecma (idecabtagene vicleucel), approved 2021: Multiple Myeloma.

Empliciti (elotuzumab), approved 2015: Multiple Myeloma.

Revlimid (lenalidomide): Multiple Myeloma (since 2006), Mantle Cell Lymphoma (since 2013), Myelodysplastic Syndromes (since 2005).

Pomalyst (pomalidomide), approved 2013: Multiple Myeloma.

And 8 more: see the FDA-approved drugs section on this page.

Still in development: Admilparant (Phase 3), Sotyktu (Phase 3), Mezigdomide (Phase 3).

Source: the FDA's openFDA label database, matched to the rare diseases on Trial Friend; the list updates automatically and can include older products.

Yes, for 14 of its FDA-approved rare disease medicines that we track, each checked on Bristol Myers Squibb's own website.

Zeposia: ZEPOSIA 360 Support, 1-833-937-6742. Offers copay help with private insurance, a short-term supply while insurance is decided and insurance help. Checked September 24, 2026.

Camzyos: MyCAMZYOS Patient Support, 1-855-226-9967. Offers copay help with private insurance, a free medicine program, a short-term supply while insurance is decided and insurance help. Checked November 2, 2026.

Reblozyl: BMS Access Support, 1-800-861-0048. Offers copay help with private insurance and insurance help. Checked September 24, 2026.

Augtyro: BMS Access Support, 1-800-861-0048. Offers copay help with private insurance, a free medicine program, a short-term supply while insurance is decided and insurance help. Checked November 9, 2026.

Abecma: Cell Therapy 360, 1-888-805-4555. Offers copay help with private insurance, travel help and insurance help. Checked November 4, 2026.

Empliciti: BMS Access Support, 1-800-861-0048. Offers copay help with private insurance and insurance help. Checked November 4, 2026.

The other 8 are on the help paying page.

Medicare and Medicaid: drugmaker copay cards are limited to private insurance, so people with government coverage usually look to a free medicine program or a charity fund, both on the help paying page.

Eligibility is decided by each program, so call the number listed before a prescription is filled.